 Connection
Teri Schreiner to Immunologic Factors
This is a "connection" page, showing publications Teri Schreiner has written about Immunologic Factors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.892 |
|
|
|
-
Abrams AW, Waltz M, Casper TC, Aaen G, Benson LA, Bernfeld EM, Charvet LE, Chitnis T, Francisco C, Gorman MP, Graves JS, Krupp L, O'Neill K, Lotze TE, Mar S, Ness J, Rensel M, Rodriguez M, Rose J, Rutatangwa A, Schreiner T, Shukla N, Tillema JM, Weinstock-Guttman B, Wheeler Y, Waubant E, Krysko KM. Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis. Ann Neurol. 2026 03; 99(3):715-729.
Score: 0.195
-
Wright MA, Barney BJ, Peterson S, Waltz M, Rose J, Rensel M, Abrams A, Waubant E, Wheeler Y, Rodriguez M, Tillema JM, Krupp L, Gorman M, Benson L, Lotze T, Shukla N, Mar S, Chitnis T, Schreiner T, Vignos M, Casper TC. Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry. J Child Neurol. 2026 Apr; 41(4):545-555.
Score: 0.194
-
Mar S, Valeriani M, Steinborn B, Schreiner T, Waubant E, Filippi M, Kotulska K, Mazurkiewicz-Beldzinska M, El Azzouzi B, Lin CJ, Shen YA, Kletzl H, Evershed J, Hogea A, Manlius C, Bonati U, Banwell B. Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study. J Neurol. 2025 Jan 15; 272(2):137.
Score: 0.185
-
Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 02 12; 92(7):e723-e732.
Score: 0.122
-
Schwartz CE, Grover SA, Powell VE, Noguera A, Mah JK, Mar S, Mednick L, Banwell BL, Alper G, Rensel M, Gorman M, Waldman A, Schreiner T, Waubant E, Yeh EA. Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis. Mult Scler. 2018 02; 24(2):175-185.
Score: 0.107
-
Virupakshaiah A, Schoeps VA, Race J, Waltz M, Sharayah S, Nasr Z, Moseley CE, Zamvil SS, Gaudioso C, Schuette A, Casper TC, Rose J, Flanagan EP, Rodriguez M, Tillema JM, Chitnis T, Gorman MP, Graves JS, Benson LA, Rensel M, Abrams A, Krupp L, Lotze TE, Aaen G, Wheeler Y, Schreiner T, Waldman A, Chong J, Mar S, Waubant E. Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease. J Neurol Neurosurg Psychiatry. 2024 Dec 16; 96(1):68-75.
Score: 0.046
-
Nasr Z, Casper TC, Waltz M, Virupakshaiah A, Lotze T, Shukla N, Chitnis T, Gorman M, Benson LA, Rodriguez M, Tillema JM, Krupp L, Schreiner T, Mar S, Rensel M, Rose J, Liu C, Guye S, Manlius C, Waubant E. Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab. Mult Scler Relat Disord. 2024 Jul; 87:105647.
Score: 0.044
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|